Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China

OBJECTIVE: The purpose of this study was to evaluate the cost-effectiveness of the combined use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine-cisplatin as the first-line treatment for patients with non-small cell lung cancer (NSCLC) in China. METHODS: A decision-...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Ruxu, Liu, Jinyu, Wu, David Bin-Chia, Qian, XinYu, Lyu, Boxiang, Zhang, Yu, Luo, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901062/
https://www.ncbi.nlm.nih.gov/pubmed/31824194
http://dx.doi.org/10.2147/CMAR.S219722

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901062/
https://www.ncbi.nlm.nih.gov/pubmed/31824194
http://dx.doi.org/10.2147/CMAR.S219722

Ejemplares similares